Please use this identifier to cite or link to this item:
|Title:||Dosing modifications of targeted cancer therapies in patients with special needs: Evidence and controversies|
|Keywords:||Administration and dosage|
|Citation:||Ng, T., Chan, A. (2012-01). Dosing modifications of targeted cancer therapies in patients with special needs: Evidence and controversies. Critical Reviews in Oncology/Hematology 81 (1) : 58-74. ScholarBank@NUS Repository. https://doi.org/10.1016/j.critrevonc.2011.02.006|
|Abstract:||Targeted therapies have revolutionized the treatment of malignancies over the past decade. These agents are generally regarded to posses fewer systemic side effects than traditional cytotoxic chemotherapies. However, patients manifesting organ dysfunction or drug interactions with concurrent medications may require dosing modifications of their targeted therapies in order to reduce the risk of systemic toxicities or reduction of drug efficacies. Studies have shown that wide variations and controversies exist with regard to dosing modifications of drugs, due to the lack of well conducted studies and consensus. Hence, this review was conducted to review the literature on the dosing modification strategies, for 30 commercially available targeted cancer drugs, and to evaluate the current mainstay recommendations and controversies. © 2011 Elsevier Ireland Ltd.|
|Source Title:||Critical Reviews in Oncology/Hematology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 15, 2018
WEB OF SCIENCETM
checked on May 23, 2018
checked on Jun 8, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.